M. Avium WGS During Mav-PD Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-13

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere.

The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mycobacterium Avium Intracellulare Complex (MAC) Study

NCT00826423

Mycobacterium Avium Intracellulare Complex (MAC)

COMPLETED

Hypertonic Saline for MAC

NCT04921943

Nontuberculous Mycobacterial Lung Disease Nontuberculous Mycobacterium Infection

RECRUITING PHASE4

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677543

Mycobacterium Infections, Nontuberculous

COMPLETED PHASE3

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

NCT05824988

Mycobacterium Avium Complex Mycobacterium Avium-Intracellulare Infection Gram-Positive Bacterial Infections +1 more

RECRUITING

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

NCT00523926

Tuberculosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mycobacterium Avium complex (MAC) are a subset of nontuberculous mycobacteria (NTM) that are typically found in the soil and water and can cause pulmonary lung disease. Treatment of MAC is challenging as it typically requires the use of three or more antibiotics for over a long period of time and the rate of eradication is suboptimal.

Mac-WGS is an observational study that aims to understand whether new strains of M. avium are responsible for persistently culture-positive sputum during treatment. Whole genome sequencing (WGS) will be performed on M. avium isolates from the sputum of patients with Mav-PD, over the duration of the study. Additionally, home environmental samples will be collected and sequenced to identify any home source of infection.

As an observational study, participants will receive routine standard of care treatment as per discretion of the physician. Standard of care includes monthly sputum submissions. The M. avium isolated from the sputum before treatment and every three months while on treatment (until such time that the sputum becomes culture-negative) will be analyzed by WGS. If sputum becomes culture-positive again, the isolated germ will also be analyzed by whole genome sequencing. It will be determined whether the identical strain of M. avium is always present or whether more than one strain is present which would suggest either multi-strain infection or the acquisition of new strains of M. avium while on treatment. Additionally, participant's home environmental samples (i.e. faucets and showerhead biofilms) will be cultured to determine whether M. avium can be recovered and if so, it will be analyzed with WGS to assess whether it is the same strain as in the participant's sputum.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mycobacterium Avium Mycobacterium Infections, Nontuberculous Mycobacterium Infections Nontuberculous Mycobacterial Lung Disease Respiratory Tract Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whole genome sequencing testing

Whole genome sequencing

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 and older
* Willing to provide informed consent and participate in study procedures
* Residing continuously in Ontario during the past five years
* Mav-PD, either initial or recurrent (previously treated patients will be eligible) five years
* Meet American Thoracic Society (ATS) / Infectious Diseases Society of America (IDSA) NTM disease criteria for Mav-PD

Exclusion Criteria

* Lack of an available pre-treatment M. avium isolate in the PHOL isolate bank
* The inability to produce sputum either spontaneously or by induction with nebulized hypertonic saline
* Cavitation \>3 cm internal diameter
* Known macrolide-resistant MAC infection
* HIV infection
* Known diagnosis of cystic fibrosis
* History of solid organ or hematological transplantation
* Severe comorbid illness that is reasonably expected to limit survival to \<24 months
* Residing in mid/north York region (King, Aurora, Newmarket, Whitechurch-Stouffville, East Gwillimbury or Georgina)
* Having moved between regions (Toronto/southern York region vs non-Toronto/York region vs mid-northern York region) within the past 5 years

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Theodore (Ted) Marras

Director, Toronto Western Hospital / University Health Network Nontuberculous Mycobacterial Disease Program, Principal Investigator, Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR